<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443076</url>
  </required_header>
  <id_info>
    <org_study_id>MB-1705</org_study_id>
    <nct_id>NCT03443076</nct_id>
  </id_info>
  <brief_title>Bioavailability of EPA + DHA in a SMEDS Formulation</brief_title>
  <official_title>A Randomized, Crossover Study to Assess the Relative Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid in a Self-micro-emulsifying Delivery System (SMEDS) Formulation Compared With a Standard Omega-3-acid Ethyl Ester Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Center for Metabolic and Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmavite</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Center for Metabolic and Cardiovascular Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) +
      docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation
      compared with a standard omega-3-acid ethyl ester product in healthy men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Actual">April 15, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline-adjusted, dose-normalized geometric mean ratio for SMEDS/Lovaza for EPA + DHA area under the curve (AUC) 0-24 hours</measure>
    <time_frame>0-24 h on Days 0-1 and on Days 14-15</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>EPA + DHA in SMEDS Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA + DHA (Lovaza)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA + DHA in SMEDS Formulation</intervention_name>
    <description>A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation</description>
    <arm_group_label>EPA + DHA in SMEDS Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>A single dose of 840 mg EPA + DHA administered as Lovaza</description>
    <arm_group_label>EPA + DHA (Lovaza)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 18.50-29.99 kg/m2

          -  Good health on basis of medical history and routine laboratory tests

          -  Score of at least 7 on vein access scale

          -  Willing and able to remain at site for extended testing periods, including a total of
             4 overnight stays, and to consume foods and products provided by study staff on those
             days

          -  Willing to abstain from alcohol for 24 h prior to clinic admission

          -  No plans to change smoking habits or other nicotine use

          -  Willing to undergo 13 venipunctures during each treatment period

        Exclusion Criteria:

          -  Screening lab test of clinical significance

          -  Positive urine drug screen

          -  Clinically significant endocrine, cardiovascular, renal, hepatic, pulmonary,
             pancreatic, neurologic, gastrointestinal or biliary disorder

          -  Uncontrolled hypertension

          -  Recent history or presence of cancer

          -  Difficulty swallowing capsules

          -  Recent blood donation or blood loss

          -  Recent consumption of high-dose fish oil or fish

          -  Recent use of any prescribed medication or over-the-counter medicinal products,
             including herbal or dietary supplements (except daily omega-3 fatty acid-free vitamin
             and/or mineral supplement or occasional use of acetaminophen or non-steroidal
             anti-inflammatory drugs)

          -  Signs or symptoms of active infection or has recently taken antibiotics

          -  Recent history or strong potential for drug or alcohol abuse

          -  Pregnant, planning to be pregnant during the study, lactating or of childbearing
             potential and unwilling to commit to use of a medically approved form of contraception
             throughout the study (note: hormonal contraceptive use is not allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Maki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MB Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MB Clinical Research, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

